The Spring Statement 2025 delivered by Chancellor Rachel Reeves has brought to light several critical issues that will undoubtedly impact the medical device companies in the UK, as well as the broader medical technology and healthcare sectors.
The Office for Budget Responsibility (OBR) has halved the UK growth forecast for 2025 from 2% to 1%, which is a significant concern for businesses across the board.
One of the key takeaways from the statement is the reduction in social funding, which is expected to push a quarter of a million people, including 50,000 children, into poverty by the end of the decade. This reduction in funding will have a direct impact on the NHS, as it will likely lead to increased demand for healthcare services while simultaneously straining resources. The Chancellor’s announcement of cuts to spending plans and lower economic growth forecasts further exacerbates the challenges faced by the healthcare sector.
For medical device companies, the reduction in social funding and the overall economic slowdown could result in decreased investment in innovation and development. Companies may find it more difficult to secure funding for new projects, and there could be a slowdown in the adoption of new technologies within the NHS. This is particularly concerning given the vital role that medical devices play in improving patient outcomes and enhancing the efficiency of healthcare delivery. Moreover, the broader medical technology sector may also face challenges due to the economic downturn. The Chancellor’s speech highlighted the need for “tough choices” and the importance of prioritising spending, which could lead to reduced support for research and development initiatives. This could hinder the progress of medical technology advancements and limit the ability of companies to bring new and innovative products to market.
In conclusion, while the Spring Statement 2025 has outlined several measures aimed at addressing the current economic challenges, it is clear that the medical device companies and the broader healthcare sector will need to navigate a complex and challenging landscape. The reduction in social funding and the lower growth forecast will require businesses to adapt and find new ways to innovate and deliver value to the NHS and patients. As Chief Executive of Medilink North of England, I am committed to supporting our members through these challenging times and ensuring that we continue to drive forward the development of medical technologies that can make a real difference in healthcare.
Tom Elliott, Chief Executive Officer
Medilink North of England
Following the Spring Statement, our corporate partners MHA now have some great insights and resources with key economic analysis available on their website, including:
